Novo Holdings, the controlling shareholder of Novo Nordisk , hopes to double the size of its recently acquired contract ...
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
At least four analysts weighed in on the prospects for Europe’s second-largest company, Novo Nordisk, after the Danish ...
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...
UBS analyst Jo Walton maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of DKK750.00. The company’s ...
14hon MSN
The CEO of obesity drugmaker Novo Nordisk and heads of other Danish companies met on Thursday with Denmark's Prime Minister ...
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback